Market News How it works Learn FAQ
| RCT 0.0827 8.67% | NU 12.59 -16.95% | EWZ 34.15 -19.82% | BBD 2.93 -28.01% | TGL 0.2427 9.57% | AZTR 1.53 113.99% | ITUB 7.7 -20.37% | XP 15.705 -48.36% | NVD 3.99 -4.77% | SRTM 0.3 -30.28% | WFF 0.0898 12.25% | SPCX 146.9 -0.40% | PBR 22.5 -13.99% | SHFS 0.094 -29.00% | SOXL 90.5 8.31% | INTC 90.47 4.04% | VALE 12 -3.23% | NVDA 216 2.39% | CLRO 4.97 52.92% | NOK 8.64 6.14% | JBLU 2.37 -9.71% | TSLL 10.76 10.25% | CRWV 55.19 1.76% | GCDT 0.1545 -12.27% | SOXS 47.98 -8.54% | RIG 6.53 1.87% | NWGL 0.0869 5.98% | ABEV 2.83 -14.24% | RWM 14.5 -0.34% | BITO 10.65 -1.66% | AAL 12.2 0.74% | GPUS 0.1785 5.68% | TSLG 5.38 10.47% | T 20.85 -0.38% | SGRY 23.25 47.62% | IREN 25.43 2.11% | INTR 4.68 -34.91% | SBS 4.73 -26.09% | NFLX 63.9 -2.96% | GRAB 2.71 -2.87% | TSLA 391.62 5.21% | QID 14.22 -2.27% | WULF 11.98 5.83% | TQQQ 68.43 3.23% | CIFR 7.71 -2.90% | RBNE 0.17 -10.53% | SID 0.9118 -22.73% | SPDN 8.5 -0.47% | VZ 43.1 -3.49% | LUCD 0.5007 21.82%
INInozyme Pharma, Inc. logo

Inozyme Pharma, Inc. (INZY)

NASDAQ Global Select · Currency in USD
$4.00 ▲ +0.01 (+0.25%)
At close: Jul 1, 4:00 PM ET. Market closed.

Summary

Previous Close
$4.00
Open
$4.00
Day's Range
$4.00 – $4.00
52 Week Range
$0.72 – $6.24
Volume
1,459,443
Avg. Volume
2,209,767
Market Cap
$258.25M
Beta (5Y Monthly)
2.29
PE Ratio (TTM)
--
EPS (TTM)
-$1.62
Earnings Date
--
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$12.00

Profile: Inozyme Pharma, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
67
CEO
Douglas A. Treco

Inozyme Pharma, Inc. operates as a biopharmaceutical entity dedicated to addressing rare diseases. Its primary mission involves pioneering treatments for disorders characterized by aberrant mineralization, which impacts the body's vascular system, soft tissues, and skeletal structure. The company's flagship therapeutic candidate, INZ-701, is an engineered, soluble protein under development to combat specific genetic conditions, namely ENPP1 and ABCC6 deficiencies, as well as for the management of calciphylaxis.

Earnings

DateEst.Actual
Aug 5, 2025-$0.36-$0.44Miss
May 14, 2025-$0.43-$0.44Miss
Mar 10, 2025-$0.42-$0.42Beat
Nov 5, 2024-$0.44-$0.39Beat
Aug 6, 2024-$0.37-$0.44Miss
May 7, 2024-$0.35-$0.38Miss

Analyst view

Consensus price target
$12.00 ▲ +200.0%
Range $4.00 – $16.00
Rating: Buy
Buy 67% · Hold 33% · Sell 0%

Get free alerts on INZY and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.